Apexus
Deloitte allianceApexus is the HRSA-designated Prime Vendor for the US 340B drug pricing program and a wholly owned subsidiary of Vizient. It negotiates sub-340B pricing and provides education and compliance services to covered entities.
- Headquarters
- Irving, TX, US
- Founded
- —
- Employees
- —
- Size
- —
- Stock exchange
- Subsidiary
- Revenue (USD)
- —
Deloitte alliance listings:
Apexus
Company profile
Apexus manages the federal 340B Prime Vendor Program under contract with HRSA, negotiating sub-ceiling drug prices and distribution arrangements for covered entities such as safety-net hospitals and community health centers. It also runs the 340B education and compliance resources used by covered entities and manufacturers. It is a subsidiary of healthcare performance improvement company Vizient.
- Ownership
- Subsidiary
- Parent company
- Vizient, Inc.
Industries served
Key offerings
340B Prime Vendor Program340B University340B compliance resources and call centerSub-ceiling pharmaceutical pricing agreements
Typical use cases
- Accessing sub-340B ceiling pharmaceutical pricing
- Training staff on 340B program compliance
- Preparing for HRSA 340B program audits
Strengths
- Sole HRSA-designated 340B Prime Vendor
- Widely used education and compliance resources
- Backing of Vizient's purchasing scale and data
Considerations
- Scope limited to the 340B program and eligible entities
- Program subject to ongoing policy and litigation changes
- Not a software platform; limited technology tooling
Typical Deloitte services
- 340B program compliance assessment
- Pharmacy and supply chain operations improvement
- Contract pharmacy and spend analytics
Editorial profile based on public information.
Apexus products
No software products listed for this company yet.